Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
In development
Reference number: GID-TA11221
Expected publication date: TBC
The appraisal committee meeting for donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease, will go ahead on 3 July 2024 as previously advised. However, this will need to be a private meeting of the committee, without public observers.
The reason the meeting needs to be in private is that we have received an update that the licence from the MHRA may not be granted by 3 July. NICE’s technology appraisal committees can only make recommendations on medicines licensed by the MHRA. So, it would not be appropriate for NICE to discuss the donanemab data in public or release any recommendations that pre-empt the MHRA decision.